Search

Your search keyword '"MacGregor G"' showing total 1,342 results
Start Over Author "MacGregor G"
1,342 results on '"MacGregor G"'

159. Regulatory toxicology and pharmacology.

Author

Axelson, Olav, Balbus, JM, Cohen, G, Davis, D, Donnay, A, Doolittle, R, Duran, BM, Egilman, D, Epstein, SS, Goldman, L, Grandjean, P, Hansen, ES, Heltne, P, Huff, J, Infante, P, Jacobson, MF, Joshi, TK, LaDou, J, Landrigan, PJ, Lee, PR, Lockwood, AH, MacGregor, G, Melnick, R, Messing, K, Needleman, H, Ozonoff, D, Ravanesi, B, Richter, ED, Sass, J, Schubert, D, Suzuki, D, Teitelbaum, D, Temple, NJ, Terracini, B, Thompson, A, Tickner, J, Tomatis, L, Upton, AC, Whyatt, RM, Wigmore, D, Wilson, T, Wing, SB, Sharpe, VA, Axelson, Olav, Balbus, JM, Cohen, G, Davis, D, Donnay, A, Doolittle, R, Duran, BM, Egilman, D, Epstein, SS, Goldman, L, Grandjean, P, Hansen, ES, Heltne, P, Huff, J, Infante, P, Jacobson, MF, Joshi, TK, LaDou, J, Landrigan, PJ, Lee, PR, Lockwood, AH, MacGregor, G, Melnick, R, Messing, K, Needleman, H, Ozonoff, D, Ravanesi, B, Richter, ED, Sass, J, Schubert, D, Suzuki, D, Teitelbaum, D, Temple, NJ, Terracini, B, Thompson, A, Tickner, J, Tomatis, L, Upton, AC, Whyatt, RM, Wigmore, D, Wilson, T, Wing, SB, and Sharpe, VA

Published
2003

164. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Author

Simes BC and MacGregor GG

Subjects
SGLT2 inhibitors, type 2 diabetes, Canagliflozin, Empagliflozin, Dapagliflozin, Ertugliflozin, Specialties of internal medicine, RC581-951
Abstract

Bryce C Simes, Gordon G MacGregor Alabama College of Osteopathic Medicine, Dothan, AL, USACorrespondence: Bryce C SimesAlabama College of Osteopathic Medicine, 445 Health Sciences Blvd., Dothan, AL 36303, USATel +1 205 904-504-8897Fax +1 205 334-699-2268Email simesbc@acom.eduAbstract: This comprehensive review covers the historical background, physiology, application in type 2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors are an insulin-independent class of oral antihyperglycemic medication that clinicians use in the treatment of type 2 diabetes. Multiple landmark clinical trials support the effectiveness of SGLT2 inhibitors in reducing blood glucose levels, but it is important to understand when to properly utilize them. SGLT2 inhibitors are the most beneficial as an adjunct medication in addition to metformin in patients with a history of cardiovascular or renal disease who need further hemoglobin A1c reduction. The novel mechanism of action also demands clinicians be aware of the side effects not typically experienced with other oral antihyperglycemic drugs, such as genital tract infections, lower leg amputations, electrolyte disturbances and bone fractures. On top of their benefits in type 2 diabetes, novel uses for SGLT2 inhibitors are being uncovered. Diabetic patients with non-alcoholic fatty liver disease, who are at an increased risk of cirrhosis and hepatocellular carcinoma, experience a clinically significant reduction in serum alanine aminotransferase levels. SGLT2 inhibitors are also effective at lowering body weight in obese individuals and decreasing systolic blood pressure. Dual SGLT1/SGLT2 inhibitors are currently being investigated as possibly the first oral medication for type 1 diabetes.Keywords: SGLT2 inhibitors, type 2 diabetes, canagliflozin, empagliflozin, dapagliflozin, ertugliflozin

Published
2019

170. Fabrication and properties of gallium phosphide variable colour displays

Author

Effer, D, Macdonald, R. A, Macgregor, G. M, Webb, W. A, and Kennedy, D. I

Subjects
Physics, Solid-State
Abstract

The unique properties of single-junction gallium phosphide devices incorporating both red and green radiative recombination centers were investigated in application to the fabrication of monolithic 5 x 7 displays capable of displaying symbolic and alphanumeric information in a multicolor format. A number of potentially suitable material preparation techniques were evaluated in terms of both material properties and device performance. Optimum results were obtained for double liquid-phase-epitaxial process in which an open-tube dipping technique was used for n-layer growth and a sealed tipping procedure for subsequent p-layer growth. It was demonstrated that to prepare devices exhibiting a satisfactory range of dominant wavelengths which can be perceived as distinct emission colors extending from the red through green region of the visible spectrum involves a compromise between the material properties necessary for efficient red emission and those considered optimum for efficient green emission.

Published
1973

Catalog

Books, media, physical & digital resources
See catalog results